NeuroDerm raises $67m in Nasdaq secondary offering

Oded Lieberman

The Israeli company, which has developed a drug delivery system for treating Parkinson's, raised 16% more than planned.

Rehovot-based drug development company NeuroDerm(Nasdaq:NDRM) has raised $67 million in its Nasdaq secondary offering at a company value of $365 million. NeuroDerm has developed a system for subcutaneous delivery of drugs for treatment of diseases, mainly Parkinson's Disease, as a substitute for the current oral delivery of the drug.

With its share price of $17, the company raised 16% more than planned compared with the share price of $15.60 when its prospectus was filed with the US Securities and Exchange Commission (SEC). With underwriters options the offering could reach as high as $75.5 million, far higher than the planned $58 million. The underwriters for the current offering are Jeffreys and Cowen & Co and the accountants are PwC Israel.

NeuroDerm's shares rose 8.3% on Nasdaq yesterday to $17.13.

The company's impressive secondary offering comes eight months after NeuroDerm raised $45 million in its IPO at $10 per share.

Managed by CEO Oded Lieberman, NeuroDerm's principal shareholders are chairman Robert Taub (19%), Uwe Wascher (17%), and Prof. Shmuel Cabilly (15.5%). Taub, a resident of Belgium and an active investor in the Israeli biomedical sector, is a cofounder of Omrix Biopharmaceuticals, sold to Johnson & Johnson for $438 million.

Like NeuroDerm, Omrix also entered the stock exchange at a substantially lower value than it initially sought (only $143 million). Also like NeuroDerm, its share posted exceptional rises in its first year of trading, and the company was eventually sold at triple its IPO value. Wascher is a close friend of Taub; the two men also jointly invested in a number of companies, including Omrix. Cabilly, an Israeli, was a researcher at Genentech who discovered a patented drug that gained that company hundreds of millions of dollars in royalties. He is also an active investor in the Israeli biomedical sector.

The company's clinical plan is undertaking a trial against the oral drug with the appropriate dosage of the drug for patients with severe cases of Parkinson's in the first half of 2015. At the same time, a trial is underway to test only the levels of the product in the blood. Results are expected by the end of the year, after which a Phase III trial will be necessary. The company hopes its product will be approved in 2018.

Published by Globes [online], Israel business news - - on July 16, 2015

© Copyright of Globes Publisher Itonut (1983) Ltd. 2015

View comments in rows
Update by email about comments talkback
Oded Lieberman
Oded Lieberman
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018